Skip to main content
Clinical Trials/NCT00039507
NCT00039507CompletedPhase 2

Pilot Study: Radiofrequency Ablation Of Resectable Non-Small Cell Lung Cancer

Fox Chase Cancer Center2 sites in 1 countryStarted: June 2002Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Locations
2

Study Overview

Brief Summary

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with surgery may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining radiofrequency ablation with surgery in treating patients who have stage I or stage II non-small cell lung cancer.

Detailed Description

OBJECTIVES:

  • Determine the acute effects of intraoperative radiofrequency tumor ablation (RFA) in patients with resectable non-small cell lung cancer.
  • Determine the treatment-related toxicity in patients treated with this therapy.
  • Determine the dimensions of the RFA lesion produced by the ablation procedure in these patients.

OUTLINE: Patients undergo intraoperative radiofrequency tumor ablation over 10-15 minutes for each tumor immediately followed by tumor resection.

PROJECTED ACCRUAL: A maximum of 20 patients will be accrued for this study.

Study Design

Study Type
Interventional
Primary Purpose
Treatment

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Other

Study Sites (2)

Loading locations...

Similar Trials

Radiofrequency Ablation During Surgery in... | Clinical Trial